In utero exposure to vigabatrin: No indication of visual field loss

Epilepsia

Volumn 50, Issue 2, 2009, Pages 318-321

  Lawthom, Charlotte ^b   Smith, Philip E M ^b   Wild, John M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Prenatal exposure; Retinal nerve fiber layer thinning; Vigabatrin; Visual field loss

Indexed keywords

CARBAMAZEPINE; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; ARTIFICIAL MILK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EYE EXAMINATION; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RETINA NERVE CELL; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MALE; PERIMETRY; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RETINAL NEURONS; TOMOGRAPHY, OPTICAL COHERENCE; VIGABATRIN; VISUAL FIELDS;

EID: 58849114517     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01700.x     Document Type: Article

References (12)

1. Abdulrazzaq YM, Padmanabhan R, Bastaki SM, Ibrahim A, Bener A 2001) Placental transfer of vigabatrin (gamma-vinyl gaba) and its effect on concentration of amino acids in the embryo of TO mice. Teratology 63 : 127 133.
2. Aventis Pharma 2001) Visual field testing with static perimetry: a guide to the testing and the interpretation of the visual field in patients receiving vigabatrin. TMG Healthcare Communications Ltd, Abingdon, Oxfordshire, UK.
3. Challier JC, Rey E, Bintein T, Olive G 1992) Passage of S(+) and R(-) gamma vinyl-gaba across the human isolated perfused placenta. Br J Clin Pharmacol 34 : 139 143.
4. Eke T, Talbot JF, Lawden MC 1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314 : 180 181.
5. Fechtner RD, Khouri AS, Figueroa E, Ramirez M, Federico M, Dewey SL, Brodie JD 2006) Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol 124 : 1257 1262.
6. Kalviainen R, Nousiainen I 2001) Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 15 : 217 230.
7. Sorri I, Herrgard E, Viinikainen K, Paakkonen A, Heinonen S, Kalviainen R 2005) Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero. Epilepsy Res 65 : 117 120.
8. Tran A, O'Mahoney T, Rey E, Mai J, Mumford JP, Olive G 1998) Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 45 : 409 411.
9. Westall CA, Buncic JR, Wright T, Cortese F, Nobile R, Panton CM 2007) Incidence of vigabatrin attributed visual toxicity is reduced in infants taking the drug for less than versus more than one year duration. Invest Ophthalmol Vis Sci 48 : E abstract 1373.
10. Wild JM, Martinez C, Reinshagen G, Harding GFA 1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40 : 1784 1794.
11. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PEM 2006) Detecting vigabatrin toxicity by imaging of the retinal nerve fibre layer. Invest Ophthalmol Vis Sci 47 : 917 924.
12. Wild JM, Ahn HS, Baulac M, Bursztyn J, Chiron C, Gandolfo E, Safran AB, Schiefer U, Perucca E 2007) Vigabatrin and epilepsy: lessons learned. Epilepsia 48 : 1318 1327.